Drug
Organoid Drug Sensitivity Testing-Guided Therapy
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
0(0%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Not yet recruiting4
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
not_yet_recruiting4100%
Recent Activity
0 active trials
Showing 4 of 4
not_yet_recruitingphase_2
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
NCT07363356
not_yet_recruitingphase_2
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers
NCT07351591
not_yet_recruitingphase_2
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
NCT07351513
not_yet_recruitingphase_2
Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer
NCT07106528
Clinical Trials (4)
Showing 4 of 4 trials
NCT07363356Phase 2
Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
NCT07351591Phase 2
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers
NCT07351513Phase 2
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma
NCT07106528Phase 2
Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4